OTHER PUBLICATIONS & ABSTRACTS
Other Data

Evidence / Other
Differential gene expression in Luminal type invasive lobular carcinoma and invasive ductal carcinoma by MammaPrint risk stratification
PUBLICATION: SABCS 2020 AUTHORS: Beth-Ann Lesnikoski, Jennifer A. Crozier, Gordan Srkalovic, Patricia Robinson, Clodia Osipo, Kalyan Banda, Heather M. Kling, Midas M. Kuilman, Josien Haan, William Audeh, and FLEX Investigators Group Background: Invasive lobular carcinoma (ILC) comprises 10-15% of breast tumors and is the second most common histological type after Read More
Differential gene expression and clinical utility of MammaPrint and BluePrint in male breast cancer patients
PUBLICATION: SABCS 2020 AUTHORS: Jennifer A. Crozier, Julie Barone, Kalyan Banda, Beth Lesnikoski, Robert Maganini, Sami Diab, Ian Grady, Thomas Lomis, Charles Cox, Amy M. Truitt, Benjamin Nota, Andrea Menicucci9, Midas Kuilman, Erin Yoder, William Audeh, FLEX Investigators Background: Male breast cancer (MaBC) is rare, comprising <1% of all breast Read More
The FLEX real world data platform explores new gene expression profiles and investigator-initiated protocols in early stagebreast cancer
PUBLICATION: SABCS 2020 AUTHORS: Laura Lee, Sami Diab, Julie Barone, Jennifer A. Crozier, Margret Chen, Rakshanda Layeequr Rahman, Robert Maganini, Douglas Marks, Amy M. Truitt, Lisa Blumencranz10, Erin Yoder10, William Audeh, Bastiaan van der Baan, FLEX Investigators Group Background: Genomic expression profiles have implications for the personalized treatment of Read More
ESMO 2020 – Hallmarks of Cancer
PUBLICATION: ESMO 2020 AUTHORS: Josien C. Haan, Rajith Bhaskaran, Lorenza Mittempergher, Ersan Lujinovic, William Audeh, Frederique Penault-Llorca and Annuska M. Glas Background: MammaPrintยฎ (MP) is a 70-gene based assay that stratifies early-stage breast cancer (EBC) patients into low and high-risk of relapse. BluePrintยฎ (BP) is an 80-gene based assay that Read More
Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial
PUBLICATION: European Journal of Cancer AUTHORS: Valesca P. Retel, Danalyn Byng, Sabine C. Linn, Katarzyna Jozwiak, Hendrik Koffijberg, Emiel J. Rutgers, Fatima Cardoso, Martine J. Piccart, Coralie Poncet, Laura J. van โt Veer, Wim H. van Harten. Abstract: The clinical utility of the 70-gene signature (MammaPrintยฎ) to guide chemotherapy Read More
ASCO 2020: TNBC Subtype
PUBLICATION: ASCO 20 AUTHORS: Virginia G. Kaklamani, Cathy Graham, Karen L. Tedesco, Abirami Sivapiragasam, Jennifer Crozier, Apurva N. Shah, Andrea Menicucci, Shiyu Wang, Michelle L. Bolner, Erin Yoder, William Audeh, FLEX Investigators' Group SUMMARY: Triple negative breast cancer (TNBC) is an aggressive histological subtype with few targeted therapies and worse Read More
ASCO 2020: HER2 Reclassification
PUBLICATION: ASCO 2020 AUTHORS: Adam Brufsky, Jennifer A. Crozier, Paul J. Chuba, Sung Ho Lee, Andrea Menicucci, Heather M. Kling, Erin Yoder, William Audeh, FLEX Investigators' Group SUMMARY: Biological heterogeneity of HER2 positive breast cancers is supported by a modest benefit of HER2- targeted therapies reported in the APHINITY and Read More